These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19157429)

  • 1. Re: It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer: I. M. Thompson, D. P. Ankerst, R. Etzioni and T. Wang J Urol 2008; 180: 1219-1222.
    Walsh PC
    J Urol; 2009 Mar; 181(3):1499; author reply 1499-500. PubMed ID: 19157429
    [No Abstract]   [Full Text] [Related]  

  • 2. It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer.
    Thompson IM; Ankerst DP; Etzioni R; Wang T
    J Urol; 2008 Oct; 180(4):1219-22. PubMed ID: 18707707
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy I. M. Thompson, C. M. Tangen, D. P. Ankerst, C. Chi, M. S. Lucia, P. Goodman, H. Parnes and C. A. Coltman, Jr. J Urol 2008; 180: 544-547.
    Atmaca AF; Balbay MD
    J Urol; 2009 May; 181(5):2387-8. PubMed ID: 19303084
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population: D. P. Ankerst, R. Miyamoto, P. V. Nair, B. H. Pollock, I. M. Thompson and D. J. Parekh J Urol 2009; 181: 2071-2076.
    Hammond I; Bunting PS
    J Urol; 2010 Jan; 183(1):396. PubMed ID: 19926100
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. S. E. Eggener, K. A. Roehl, O. Yossepowitch and W. J. Catalona, J Urol 2006; 176: 1399-1403.
    Wagner MD; Daneshmand S; Sokoloff M; Barry JM
    J Urol; 2007 Jun; 177(6):2396; author reply 2396-7. PubMed ID: 17509368
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. S. J. Freedland, E. A. Platz, J. C. Presti Jr., W. J. Aronson, C. L. Amling, C. J. Kane and M. K. Terris. J Urol, 175: 500-504, 2006.
    Stamatiou K; Alevizos A; Mariolis A; Sofras F
    J Urol; 2006 Sep; 176(3):1251-2; author reply 1252. PubMed ID: 16890735
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Monique J. Roobol, Ewout W. Steyerberg, Ries Kranse, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010;57:79-85.
    Morrod D
    Eur Urol; 2010 Sep; 58(3):327; author reply 328-30. PubMed ID: 20598799
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial: R. M. Stopiglia, U. Ferreira, M. M. Silva, W. E. Matheus, f. Denardi and L. O. Reis J Urol 2010; 183: 940-945.
    Yoon DK; Park HS; Park JY
    J Urol; 2010 Nov; 184(5):2214-5; author reply 2215. PubMed ID: 20864135
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Effectiveness of antibiotics given to asymptomatic men for an increased prostate specific antigen. S. Baltaci, E. Suer, A. H. Haliloglu, M. I. Gokce, A. H. Elhan and Y. Beduk. J Urol 2009; 181: 128-132.
    Eggener SE; Raman JD
    J Urol; 2009 Jul; 182(1):396-7. PubMed ID: 19467675
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: The 20-core prostate biopsy protocol--a new gold standard?: V. Ravery, S. Dominique, X. Panhard, M. Toublanc, L. Boccon-Gibod and L. Boccon-Gibod. J Urol 2008; 179: 504-507.
    Serefoglu EC; Ozdemir AT; Balbay MD
    J Urol; 2008 Nov; 180(5):2256-7. PubMed ID: 18804806
    [No Abstract]   [Full Text] [Related]  

  • 11. To screen or not to screen? Prostate cancer screening: why it's not for every man.
    Lefevre M
    Medscape J Med; 2008; 10(8):181. PubMed ID: 18924633
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Weckermann D, Harzmann R. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur Urol 2004;46:279-84.
    Weston P; Persson BE
    Eur Urol; 2005 Mar; 47(3):422; author reply 422. PubMed ID: 15716212
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostate cancer diagnosis: importance of individualized risk stratification models over PSA alone.
    Chun FK; Karakiewicz PI; Briganti A
    Eur Urol; 2008 Aug; 54(2):241-2. PubMed ID: 18538466
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Editorial: the central role of prostate specific antigen in diagnosis and progression of prostate cancer.
    Lawrence G
    J Urol; 1996 Aug; 156(2 Pt 1):484. PubMed ID: 8683715
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Prospective evaluation of operating characteristics of prostate cancer detection biomarkers: Y. Liang, D. P. Ankerst, N. S. Ketchum, B. Ercole, G. Shah, J. D. Shaughnessy, Jr., R. J. Leach and I. M. Thompson J Urol 2011; 185: 104-110.
    Catalona WJ
    J Urol; 2011 Nov; 186(5):2131-2; author reply 2132. PubMed ID: 21945513
    [No Abstract]   [Full Text] [Related]  

  • 16. Upcoming evidences on prostate-specific antigen-based screening for men at risk of prostate cancer.
    Boscolo-Berto R
    Int J Urol; 2009 Sep; 16(9):711. PubMed ID: 19769655
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostate-specific antigen in black men.
    Catalona WJ
    N Engl J Med; 1997 Jan; 336(2):134-5; author reply 135-6. PubMed ID: 8992341
    [No Abstract]   [Full Text] [Related]  

  • 18. Weighing the benefits and downsides of prostate-specific antigen screening.
    Pignone M
    Arch Intern Med; 2009 Sep; 169(17):1554-6. PubMed ID: 19786672
    [No Abstract]   [Full Text] [Related]  

  • 19. Why do I need a prostate exam when my PSA levels are normal?
    Mayo Clin Health Lett; 2006 Apr; 24(4):8. PubMed ID: 16649264
    [No Abstract]   [Full Text] [Related]  

  • 20. It's sometimes safe to delay prostate surgery. "Watchful waiting" plus active surveillance still leaves a window of opportunity if surgery is necessary.
    Health News; 2006 Jun; 12(6):13-4. PubMed ID: 16832884
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.